PegBio Co

PegBio Co P/TBV

The Price to Tangible Book Value (P/TBV) of PegBio Co (2565.HK) as of Oct 15, 2026 is 51.34. In the previous year, Price to Tangible Book Value (P/TBV) was 448.63 — a change of -88.56% (lower).

P/TBV

51.34

YoY

-88.56%

Last updated:

Price to Tangible Book Value (P/TBV) of PegBio Co is 2025 51.34 . Price to Tangible Book Value (P/TBV) of PegBio Co was 2024 448.63 . It decreases by -88.56% lower compared to the previous year.

The PegBio Co P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2022
76.76 CNY
Jan 1, 2023
121.90 CNY
Jan 1, 2024
448.63 CNY
Jan 1, 2025
51.34 CNY
The PegBio Co P/TBV history
YEARP/TBVYoY
51.34-88.56%
448.63+268.04%
121.90+58.79%
76.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co Ltd is a biotechnology company based in Hangzhou, China, operating within the healthcare sector. The company focuses on the research, development, and production of innovative drugs targeting chronic disease treatment. PegBio is set to go public with an IPO scheduled for May 27, 2025, under the ticker 2565.HK. The company's website is https://www.pegbio.com/. PegBio's primary product, PB-119, is described as a self-developed, near-commercialized long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. GLP-1 is a peptide hormone involved in blood sugar regulation. The company also lists several product candidates, including PB-718, PB-1902, PB-722, PB-2301, and PB-2309. These products are intended for the treatment of various chronic and metabolic conditions, such as type 2 diabetes mellitus (T2DM), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. Congenital hyperinsulinemia is a rare endocrine disorder characterized by persistent low blood sugar levels. PegBio's focus areas include metabolic diseases and chronic conditions requiring ongoing therapeutic management. The company's operational headquarters is located in Hangzhou, Zhejiang Province, China. As a biotechnology firm, PegBio operates within the broader healthcare industry, emphasizing drug development for unmet medical needs in chronic disease management. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Price to Tangible Book Value (P/TBV) of PegBio Co is 51.34 in 2025.

Price to Tangible Book Value (P/TBV) of PegBio Co changed from 448.63 to 51.34, representing a -88.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) PegBio Co since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s PegBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PegBio Co

All Key Metrics — PegBio Co